SF3B1 and melanoma: The finding of SPRED1 as a driver increases the proportion of mucosal melanoma samples with a known driver event in the MAPK pathway (NF1, NRAS, BRAF, SF3B1, TP53, KIT, and SPRED1) to 92% of the studied patients.